New health insurance coverage created by the 2010 health reform law will attract a lower-income, less-educated and more diverse set of customers than the insurance markets that exist today, according to a new analysis by PricewaterhouseCoopers. And that could create challenges for doctors and hospitals trying to care for those patients.
Three area hospital groups—St. Vincent Health, Community Health Network and Suburban Health Organization—have agreed to join forces to manage patients’ health and strike new kinds of contracts with employers and health insurers.
With volunteer leader Nancy Shepard at the helm, IWIN Foundation has distributed $875,000 in grants to breast cancer patients. Recipients have ranged in age from 18 to 90.
Sam Odle, who retired from Indiana University Health in July as chief operating officer, is joining the local lobbying firm as a senior policy adviser, representing clients in the health care and life sciences sectors.
The departure of Dr. George Sledge likely will sap the breast cancer research program at the Indiana University Melvin and Bren Simon Cancer Center of about $500,000 in annual funding. But the program Sledge built over the past three decades mostly will remain intact.
It would be “absurd” and a “travesty” for Indiana not to expand its Medicaid program, according to two local hospital officials. And yet other health care leaders do not expect expanded Medicaid coverage to provide nearly as much help to uninsured Hoosiers as hoped.
With health insurance premiums continuing to outstrip inflation, some health insurers and hospital systems are considering bringing back an old strategy: limiting patient access to a “narrow” network of doctors and hospitals.
The looming shortage of nurses and the faculty to educate nurses threatens Americans’ access to quality health care. As our population ages and health care becomes more extensive and complex, an increasing demand for highly educated nurses persists. This need directly influences the necessity for nursing faculty.
Federal and state prosecutors have collected more than $30 billion from drug companies for alleged fraud and illegal marketing over the last 20 years, according to a new report by consumer advocacy group Public Citizen.
If Indiana expands its Medicaid program as called for under President Obama’s health reform law, it likely will hike state spending on the program an extra 13.5 percent—or $516 million annually—by 2020, according to the latest projections from Seattle-based actuarial firm Milliman Inc.
Novo Nordisk A/S, the world’s largest insulin maker, plans to spend $100 million on research in China. The move follows a similar one by Indianapolis-based Eli Lilly, which opened a 150-person research center in Shanghai in May.
A European committee has endorsed the use of Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate.
Mainstreet Property Group LLC plans to build a 100-bed facility at 16th Street and Arlington Avenue on nine acres where Raytheon Technical Services Co. LLC once operated.
The Indianapolis-based health insurer expects the purchase of health insurance to look and feel much more like online retailing than ever before, where brand name, along with price and convenience, win the day.
Purdue University’s Regenstrief Center for Healthcare Engineering will get another $10 million from the Indianapolis-based Regenstrief Foundation, keeping its research going through 2018.
A large physician practice in Bloomington remains at an impasse with Anthem Blue Cross and Blue Shield of Indiana less than two months before their contract is set to expire.
Bloomington-based Cook Medical announced a new division to capitalize on the growing market for minimally invasive procedures to fix problems in ears, noses and throats, as well as other maladies of the head and neck.
A $6.4 billion accord for U.S. drug and medical-device reviews is set to unravel just three months after taking effect as lawmakers squabble over budget cutbacks.
Indianapolis-based Nyhart Actuary & Employee Benefits has established its first office on the West Coast with its latest acquisition.
Eli Lilly and Co. said Thursday that its cancer drug Alimta didn’t extend overall survival when combined with Roche Holding AG’s Avastin in patients with a form of lung tumor.
